FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

Amneal Generic OTC Narcan Spray OKd

FDA approves an Amneal Pharmaceuticals ANDA for a generic over-the-counter naloxone hydrochloride nasal spray, 4mg, (generic Narcan) for treating a dr...

latest-news-card-1
Human Drugs

Cut Ozempic/Wegovy Price: HELP Committee

Sen. Bernie Sanders and the HELP Committee call on Novo Nordisk to significantly reduce the cost of its Ozempic and Wegovy in the U.S.

latest-news-card-1
Medical Devices

Curio Postpartum Depression Device Cleared

FDA clears a Curio Digital Therapeutics 510(k) for its MamaLift Plus, a prescription digital therapeutic for treating postpartum depression.

latest-news-card-1
Human Drugs

Zydus Lifesciences Issued Another FDA-483

An FDA inspection at Zydus Lifesciences injectable manufacturing site in Jarod, India results in a 10-observation Form FDA-483, the second received by...

latest-news-card-1
Human Drugs

Dr. Reddys Recalls Sapropterin Dihydrochloride

Dr. Reddys Laboratories recalls six lots of sapropterin dihydrochloride powder for oral solution 100 mg due to decreased potency.

latest-news-card-1
Human Drugs

Pivya Approved for Uncomplicated UTIs

FDA approves Utility Therapeutics Pivya for some uncomplicated urinary tract infections.

latest-news-card-1
Human Drugs

Boehringer on Improving Informed Consent Guide

Boehringer Ingelheim suggests several modifications to an FDA draft guidance on key information and facilitating understanding in informed consent.

latest-news-card-1
Marketing

Biological Promotion Q&A Guidance

FDA publishes a draft guidance with questions and answers on promotional communications for some prescription biologics.

latest-news-card-1
Human Drugs

State Lack of Fenofibrate CV Benefit: Petition

The educational group Healthy Women petitions FDA to change fenofibrate labeling to state there is no proven cardiovascular benefit to using fenofibra...

latest-news-card-1
Biologics

Priority Review for Jemperli sBLA

FDA accepts for priority review a GSK supplemental BLA for Jemperli (dostarlimab) for combination use with standard-of-care chemotherapy (carboplatin ...